Interleukin 1β receptor blocker (anakinra) and regenerative stem cell therapy: two novel approaches effectively ameliorating diabetic cardiomyopathy

HIGHLIGHTS

• What: The authors aimed to carry out the current research to explore the role of two novel therapeutic approaches: one a biological drug aimed to block inflammatory signaling of the 1beta (IL1β) axis namely anakinra; the other is provision of anti-inflammatory regenerative stem cells. This study was carried out at the Physiology and Biochemistry Departments, Faculty of Medicine, Cairo University. The authors have also explored the effect of IL1β receptor direct blocking using Anak.
• Who: Lamiaa Mohamed Mahmoud from the Department of Physiology, Faculty of Medicine, Cairo have published the research: Interleukin 1β receptor . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.